Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam L Boxer

Showing results (201-210 of 300) with videos related to

Pageof 30
Sort By:
The Lancet. Neurology|January 25, 2025
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trialKristy K L Coleman, Scott Berry, Jeffrey Cummings, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Alterations in Lysosomal, Glial and Neurodegenerative Biomarkers in Patients with Sporadic and Genetic Forms of Frontotemporal DementiaJennifer Hsiao-Nakamoto, Chi-Lu Chiu, Lawren VandeVrede, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 2, 2023
[<sup>18</sup>F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar DegenerationGanna Blazhenets, David N Soleimani-Meigooni, Wesley Thomas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 2, 2013
TDP-43 frontotemporal lobar degeneration and autoimmune diseaseZachary A Miller, Katherine P Rankin, Neill R Graff-Radford, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersJesús Garcia Castro, Lídia Vaqué-Alcázar, Lawren VandeVrede, et al.
Nature Medicine|May 14, 2024
Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim resultsJeffrey Sevigny, Olga Uspenskaya, Laura Dean Heckman, et al.
JAMA Network Open|April 29, 2022
Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal DegenerationIgnacio Illán-Gala, Salvatore Nigro, Lawren VandeVrede, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 20, 2020
The impact of demographic, clinical, genetic, and imaging variables on tau PET statusRik Ossenkoppele, Antoine Leuzy, Hanna Cho, et al.
JAMA Neurology|June 28, 2021
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance ImagingRik Ossenkoppele, Ruben Smith, Niklas Mattsson-Carlgren, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 13, 2025
Blood-based Alzheimer's disease biomarkers in a behavioral neurology clinic: Real-world implementation, clinical utility, and diagnostic performanceIgor Prufer Q C Araujo, Tara Ellingson, Nicholas U Schwartz, et al.
Pageof 30

Showing results (201-210 of 300) with videos related to

Sort By:
Pageof 30
The Lancet. Neurology|January 25, 2025
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trialKristy K L Coleman, Scott Berry, Jeffrey Cummings, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Alterations in Lysosomal, Glial and Neurodegenerative Biomarkers in Patients with Sporadic and Genetic Forms of Frontotemporal DementiaJennifer Hsiao-Nakamoto, Chi-Lu Chiu, Lawren VandeVrede, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 2, 2023
[<sup>18</sup>F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar DegenerationGanna Blazhenets, David N Soleimani-Meigooni, Wesley Thomas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 2, 2013
TDP-43 frontotemporal lobar degeneration and autoimmune diseaseZachary A Miller, Katherine P Rankin, Neill R Graff-Radford, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersJesús Garcia Castro, Lídia Vaqué-Alcázar, Lawren VandeVrede, et al.
Nature Medicine|May 14, 2024
Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim resultsJeffrey Sevigny, Olga Uspenskaya, Laura Dean Heckman, et al.
JAMA Network Open|April 29, 2022
Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal DegenerationIgnacio Illán-Gala, Salvatore Nigro, Lawren VandeVrede, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 20, 2020
The impact of demographic, clinical, genetic, and imaging variables on tau PET statusRik Ossenkoppele, Antoine Leuzy, Hanna Cho, et al.
JAMA Neurology|June 28, 2021
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance ImagingRik Ossenkoppele, Ruben Smith, Niklas Mattsson-Carlgren, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 13, 2025
Blood-based Alzheimer's disease biomarkers in a behavioral neurology clinic: Real-world implementation, clinical utility, and diagnostic performanceIgor Prufer Q C Araujo, Tara Ellingson, Nicholas U Schwartz, et al.
Pageof 30